Protocolo diagnóstico y terapéutico de las alteraciones de la hemostasia en el embarazo

  1. Sierra Aisa, C.
  2. Moretó Quintana, A.
  3. Iruín Irulegui, G.
  4. Martín Martitegui, X.
  5. García-Ruiz, J.C.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2016

Serie: 12

Número: 22

Páginas: 1293-1298

Tipo: Artículo

DOI: 10.1016/J.MED.2016.10.023 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

Abstract Introduction Venous thromboembolism (VTE) is one of the leading causes of maternal mortality in developed countries. On the other hand, women with congenital bleeding disorders during pregnancy, childbirth and postpartum often have an increased risk of bleeding. Thrombosis and pregnancy The diagnosis of VTE during pregnancy can be a challenge because many of its symptoms can occur associated with a normal pregnancy. Low molecular weight heparins are the treatment of choice for ETV that occurs during this period. Congenital coagulopathies and gestation Sometimes postpartum hemorrhage is the first manifestation of a congenital coagulopathy, usually Von Willebrand disease, since other coagulopathies are rare entities.

Referencias bibliográficas

  • Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO; American College of Chest Physicians. VTE, thrombo-philia, antithrombotic therapy, and pregnancy: antithrombotic the-rapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:2Suppl: e691S-736.
  • Green-top Guideline No. 37b — thromboembolic disease in pregnancy and the puerperium: acute management. London: Royal College of Obstetricians and Gynaecologists; 2015. Disponible en : https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37b.pdf).
  • carsbrook AF, Evans AL, Owen AR, Gleeson FV. Diagnosis of suspected venous thromboembolic disease in pregnancy.Clin Radiol. 2006;61(1):1-12.
  • Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005; 106(2):401-7.
  • Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, et al. Compression stockings to prevent postthrombotic syndrome: a rando-mised placebo-controlled trial. Lancet. 2014;383(9920):880-8.
  • Clark P. Changes of hemostasis variables during pregnancy. Sem Vasc Med. 2003;3:13-24.
  • Giangrande PLF. Pregnancy in women with inherited bleeding disorders. En: Treatment of Hemophilia. nº 29. Montreal: World Federation of Hemophilia; 2003. Disponible en: https://www.hae-mophilia.ie/pdf/Pregnancy.pdf
  • Hromadnikova I, Houbova B, Hridelova D, Voslarova S, Kofer J, Komrs-ka V, et al. Replicate real-time PCR testing of DNA in maternal plasma increases the sensitivity of non-invasive fetal sex determination. Pregnat Diagn. 2003;23:235-8.
  • Rigby FB, Nolan TE. Inherited disorders of coagulation in preg-nancy. Clin Obst Gynecol. 1995;38:497-513.
  • Catanzarite VA, Novontny WF, Cousins LM, Schneider JM. Pregnancies in a patient with congenital absence of prothrombin activity: case report. Am J Perinatol. 1997;14:135-8.
Fuente de los datos: Dialnet